To test whether CDH22 expression can be dynamically modulated by epigenetic mechanisms, a panel of six BC cell lines and one immortalised but non-neoplastic mammary cell line (HBL-100) were treated with two epigenetic drugs (AZA and TSA). The gene discussed is CDH22; the disease is breast cancer.